Inhibiting CSF-1 to treat TGCT was validated by Turalio, a twice-daily Daiichi Sankyo drug that won its FDA approval in this indication in 2019. But Turalio’s label carries a black box warning ...
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. Fellow Japanese drugmaker Ono Pharmaceutical has won an FDA green light for vimseltinib to treat ...
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...
The biotech is hoping to provide an alternative to Daiichi Sankyo’s Turalio (pexidartinib), an oral CSF-1, KIT, and FLT3 inhibitor, which was given the green light by the FDA in 2019 ...
If it makes it to market, the drug will compete with Daiichi Sankyo's Turalio (pexidartinib), a CSF1R, KIT, and FLT3 inhibitor that was cleared for TGCT by the FDA in 2019, and potentially Ono's ...
It will compete with Daiichi Sankyo’s CSF1R inhibitor pexidartinib (Turalio), which secured FDA approval in TGCT in 2019. TGCT are rare, non-malignant tumours that form in and near joints.
A phase III trial showed a higher objective response rate with Romvimza than a separate phase III trial showed with Daiichi Sankyo Co. Ltd.’s Turalio (pexidartinib), and the latter’s label contains a ...
Hosted on MSN26d
Ono’s TGCT therapy wins FDA approval, challenging Daiichi SankyoOno Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza (vimseltinib) to treat tenosynovial giant cell tumour (TGCT), introducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback